Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06715124 · ClinicalTrials.gov registry record · Phase 1
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
A Phase 1 study of Advanced Solid Tumors, sponsored by Quanta Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 237
- Enrollment target
- 10
- Study locations
NCT06715124 is a Phase 1 study of Advanced Solid Tumors that is active but no longer recruiting, run by Quanta Therapeutics. The registered enrollment target is 237 participants, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (20% higher). The trial reports 10 study locations across 8 states.
The verdict
NCT06715124, a Phase 1 study of Advanced Solid Tumors, is active but no longer recruiting, sponsored by Quanta Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 237 participants
- Enrollment target
- 10
- Study locations
Study Summary
Phase 1 study to determine the safety, tolerability, and anti-tumor activity of QTX3544 as a single agent or in combination with cetuximab.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Cetuximab
- DRUG QTX3544
Study Locations (10)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- South Texas Accelerated Research Therapeutics, LLC San Antonio - San Antonio
Utah
- Huntsman Cancer Institute, University of Utah - Salt Lake City
- South Texas Accelerated Research Therapeutics Mountain Region, LLC - West Valley City
Colorado
- Sarah Cannon Research Institute - Denver
Connecticut
- Yale Cancer Center - New Haven
Florida
- Florida Cancer Specialists & Research Institute - Sarasota
Michigan
- South Texas Accelerated Research Therapeutics, LLC Midwest - Grand Rapids
North Carolina
- Duke Cancer Center - Durham
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 237 participants |
| Start Date | 2025-01-14 |
| Est. Completion | 2029-01-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06715124
The ClinicalTrials.gov registry entry for NCT06715124 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 237 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (20% higher). The listed sponsor is Quanta Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Cetuximab is the first listed.
NCT06715124 reports 10 study locations spanning 8 distinct geographic areas - top geographies include Texas, Utah, Colorado.
Frequently Asked Questions
What is clinical trial NCT06715124 about?
NCT06715124 is a clinical study titled "QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations". Phase 1 study to determine the safety, tolerability, and anti-tumor activity of QTX3544 as a single agent or in combination with cetuximab.
What is the current status of trial NCT06715124?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 237 participants. The study started on 2025-01-14. Estimated completion is 2029-01-02.
What conditions does trial NCT06715124 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT06715124?
The interventions under investigation include: Cetuximab (COMBINATION_PRODUCT), QTX3544 (DRUG).
Who is sponsoring clinical trial NCT06715124?
This trial is sponsored by Quanta Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06715124 being conducted?
This trial has 10 study locations across Colorado, Connecticut, Florida, Michigan, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.